But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.

Ok dell’Fda al farmaco che si somministra solo due volte l’anno e potrebbe segnare un punto di svolta nella lotta a una pandemia che dura da oltre quattro decenni

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease.

Lenacapavir was nearly 100 per cent effective in preventing HIV in clinical trials.

Il lancio del lenacapavir potrà cambiare il corso dell’epidemia di Aids. Ma dovrà affrontare tuttavia i tagli proposti dall'amministrazione Trump ai finanziame…

The shot made by Gilead Sciences nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the…